Phase II trial of sorafenib in advanced thyroid cancer (Q37121708)

18 August 2017

Phase II trial of sorafenib in advanced thyroid cancer (English)

1 reference

18 August 2017

phase II clinical trial

0 references

Andrea B Troxel

0 references

Keith T Flaherty

1 reference

18 August 2017

Marcia S Brose

1 reference

18 August 2017

Vandana Gupta-Abramson

1 reference

18 August 2017

Anoma Nellore

1 reference

18 August 2017

Kanchan Puttaswamy

1 reference

18 August 2017

Maryann Redlinger

1 reference

18 August 2017

Kathy Ransone

1 reference

18 August 2017

Susan J Mandel

1 reference

18 August 2017

Laurie A Loevner

1 reference

18 August 2017

Peter J O'Dwyer

1 reference

18 August 2017

language of work or name

English

0 references

publication date

9 June 2008

1 reference

Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

4714-4719

1 reference

18 August 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Sorafenib in advanced clear-cell renal-cell carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

BRAF mutation in thyroid cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Mutations of the BRAF gene in human cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Optimal two-stage designs for phase II clinical trials

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653134

Angiogenesis inhibitors in the treatment of lung cancer

3 September 2018

1 reference

12 December 2020

Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation

1 reference

12 December 2020

Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas

1 reference

12 December 2020

1 reference

12 December 2020

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

12 December 2020

Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*

1 reference

12 December 2020

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2008.16.3279

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

18541894

1 reference